单位：万元 非经营性资金占用 资金占用方名 称 占用方与上 市公司的关 联关系 上市公司核算 的会计科目 2023 年期初 占用资金余 额 2023 年 1-6 月 占用累计发生 金额（不含利 息） 2023 年 1-6 月 占用资金的利 息（如有） 2023年1-6月 偿还累计发 生金额 2023年6月期 末占用资金 余额 占用形 成原因 占用性质 控股股东、实际控制 人及其附属企业 小计 - - - - 前控股股东、实际控 制人及其附属企业 小计 - - - - 其他关联方及附属企 业 小计 总计 - - - - 其它关联资金往来 资金往来方名 称 往来方与上 市公司的关 联关系 上市公司核算 的会计科目 2023 年期初 占用资金余 额 2023 年 1-6 月 占用累计发生 金额（不含利 息） 2023 年 1-6 月 占用资金的利 息（如有） 2023年1-6月 偿还累计发 生金额 2023年6月期 末占用资金 余额 往来形 成原因 往来性质 （经营性往来、 非经营性往来） 控股股东、实际控制 人及其附属企业 上市公司的子公司及 其附属企业 新 疆 奎 屯 天 康 植 物 蛋 白 有 限 公司 全资 ...

天康生物 证券代码：002100 证券简称：天康生物 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 天康生物股份有限公司（以下简称"公司"）第八届监事会第四次会议通知 于 2023 年 8 月 14 日以书面专人送达和电子邮件方式发出，并于 2023 年 8 月 24 日（星期四）上午 12 时以现场结合通讯表决方式召开，公司 3 名监事均参加了 会议。董事会秘书列席了会议，符合《公司法》的有关规定，会议合法有效。会 议由监事会主席张涛女士主持，会议就以下事项形成决议： 一、议案审议情况 （一）审议并通过公司《2023 年半年度报告全文及摘要》的议案；（内容详 见刊登于 2023 年 8 月 26 日本公司指定信息披露报纸《证券时报》上的《天康生 物股份有限公司 2023 年半年度报告摘要》<公告编号：2023-072>和在巨潮资讯 网 www.cninfo.com.cn 上披露的《天康生物股份有限公司 2023 年半年度报告全 文》） 同意该项议案的票数为 3 票；反对票 0 票；弃权票 0 票； 经审核，监事会认为董事会编制和审核的《天康生物股份有限公司 ...

天康生物 | 证券代码：002100 | 证券简称：天康生物 | 公告编号：2023-070 | | --- | --- | --- | | 债券代码：128030 | 债券简称：天康转债 | | 天康生物股份有限公司 关于深圳证券交易所关注函回复的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 天康生物股份有限公司（以下简称"公司"或"天康生物"）于 2023 年 8 月 9 日收悉深圳证券交易所上市公司管理一部下发的《关于对天康生物股份有限公司 的关注函》（公司部关注函[2023]第 297 号），公司董事会及管理层予以高度重视， 立即召集相关人员对交易所关注的公司控股子公司天康制药股份有限公司（以下 简称"天康制药"）拟申请在全国中小企业股份转让系统挂牌的相关问题进行了 认真核实和分析，现将关注函提出的问题回复公告如下： 问题一：结合天康制药的主营业务、未来发展规划等说明天康制药拟在全国 中小企业股份转让系统挂牌转让的原因和目的，在此基础上说明挂牌事项对公司 及股东利益的影响，公司未来三年是否继续保持对天康制药的控制。 回复说明： 1、天康制药的 ...

天康生物 证券代码：002100 证券简称：天康生物 天康生物 公告编号：2023-069 债券代码：128030 债券简称：天康转债 天康生物股份有限公司 关于 2023 年 7 月份生猪销售简报 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、2023 年 7 月份生猪销售情况 天康生物股份有限公司（以下简称"公司"）2023 年 7 月份销售生猪 25.57 万头，销量环比增长 6.99%，同比增长 54.13%；销售收入 3.31 亿元，销售收入环 比下降 10.30%，同比增长 1.22%。 2023 年 7 月份商品猪（扣除仔猪、种猪后）销售均价 13.09 元/公斤，环比下 降 4.59%。 2023 年 1-7 月，公司累计销售生猪 156.54 万头，较去年同期增长 42.65%； 累计销售收入 24.73 亿元，较去年同期增长 50.24%。 | | | | | 生猪销量 | | 销售收入 | | 商品猪价格 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 月 ...

深 圳 证 券 交 易 所 关于对天康生物股份有限公司的关注函 公司部关注函〔2023〕第 297 号 和持续盈利能力。 3. 说明天康制药与你公司之间是否存在独立竞争和持续性 交易，双方高级管理人员是否存在交叉任职，是否能保持各自资 产和财务独立，并在此基础上说明挂牌转让的相关制度安排。 天康生物股份有限公司董事会： 4. 你公司认为其他需说明的事项。 你公司于 2023 年 8 月 8 日披露的《关于控股子公司天康制 药股份有限公司拟申请新三板挂牌的公告》显示，你公司控股子 公司天康制药股份有限公司（以下简称"天康制药"）拟申请在 全国中小企业股份转让系统挂牌。我部对此表示关注，请你公司 核实并说明以下问题： 请你公司就上述问题做出书面说明，在 2023 年 8 月 16 日 前将有关说明材料报送我部并对外披露，同时抄送派出机构。同 时，提醒你公司及全体董事、监事和高级管理人员严格遵守《证 券法》《公司法》等法律法规，以及本所《股票上市规则》等规 定，真实、准确、完整、及时、公平地履行信息披露义务。 特此函告 1. 结合天康制药的主营业务、未来发展规划等说明天康制 药拟在全国中小企业股份转让系统挂牌转让的 ...

Group 1: Event Details - TianKang Biological Co., Ltd. will participate in the "2023 Xinjiang Listed Companies Investor Collective Reception Day" [1] - The event will be held online on June 16, 2023, from 15:30 to 18:00 [1] - Investors can join via the "Panorama Roadshow" website, WeChat official account, or Panorama Roadshow APP [1] Group 2: Communication Focus - Company executives will discuss the 2022 annual performance, corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [1] - The aim is to enhance interaction and communication with investors [1] Group 3: Assurance of Information - The company and its board guarantee the accuracy and completeness of the disclosed information, ensuring no false records or misleading statements [1]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 3,890,843,979.48, representing a 14.71% increase compared to CNY 3,391,929,405.09 in the same period last year[18]. - The net loss attributable to shareholders of the listed company was CNY -14,282,251.76, a significant improvement of 79.48% from CNY -69,605,796.25 year-on-year[18]. - The net profit for the current period was -17,149,045.31, compared to -108,566,710.19 in the previous period, indicating an improvement[32]. - The total comprehensive income for the current period was -7,300,826.24, compared to -188,142,159.14 in the previous period, showing a significant reduction in losses[33]. - The basic and diluted earnings per share for the current period were both -0.01, compared to -0.05 in the previous period[33]. Cash Flow - The net cash flow from operating activities improved by 35.21%, amounting to CNY -523,750,573.77, compared to CNY -808,347,021.44 in the previous year[21]. - Cash flow from operating activities resulted in a net outflow of -523,750,573.77, an improvement from -808,347,021.44 in the previous period[33]. - Cash flow from investing activities generated a net inflow of 474,080,713.81, compared to a net outflow of -204,891,989.28 in the previous period[34]. - Cash flow from financing activities resulted in a net inflow of 651,284,449.71, compared to a net outflow of -122,578,555.00 in the previous period[34]. - The company reported cash and cash equivalents at the end of the period amounting to 3,802,570,554.95, up from 2,175,960,504.84 in the previous period[34]. Assets and Liabilities - The total assets as of March 31, 2023, were CNY 20,374,771,227.30, reflecting a 5.24% increase from CNY 19,360,994,902.71 at the end of the previous year[18]. - The total liabilities as of Q1 2023 amounted to approximately RMB 10.61 billion, compared to RMB 9.70 billion in the previous year, indicating a year-over-year increase of 9.4%[30]. - Current assets rose to CNY 12,990,493,336.65, up from CNY 12,412,059,821.41, indicating an increase of about 4.65%[41]. - The total current liabilities increased to CNY 7,315,031,840.16 from CNY 6,173,714,914.84, representing a rise of about 18.46%[42]. - Non-current liabilities decreased to CNY 3,290,328,060.73 from CNY 3,522,309,214.78, showing a reduction of about 6.58%[42]. Equity and Investments - The company’s total equity attributable to shareholders was CNY 8,039,387,885.55, a slight increase of 1.13% from CNY 7,949,867,246.11 at the end of the previous year[18]. - The total equity attributable to minority shareholders was approximately RMB 1.73 billion, compared to RMB 1.72 billion in the previous year, indicating stability in minority interests[30]. - The company's long-term equity investments decreased to CNY 21,357,276.88 from CNY 105,445,142.28, a decline of approximately 79.73%[42]. Research and Development - The company increased its research and development expenditure to CNY 12,982,627.27, a rise of 68.48% from CNY 7,705,622.64 in the previous year[7]. - Research and development expenses for Q1 2023 were approximately RMB 40.16 million, slightly up from RMB 38.13 million in Q1 2022, indicating a focus on innovation[30]. Management and Operational Efficiency - The company reported a decrease in management expenses by 28.63%, amounting to CNY 104,830,863.20 compared to CNY 146,883,773.68 in the previous year[7]. - The company reported a decrease in management expenses to approximately RMB 104.83 million from RMB 146.88 million, showing improved cost management[30]. - The company recorded operating profit of 10,831,007.05, a significant recovery from -87,755,749.48 in the previous period[32]. Strategic Acquisitions - The company completed the acquisition of 100% equity in Guanjie Company, which is now a wholly-owned subsidiary, enhancing its market position[26]. - The company plans to acquire a 100% stake in Guanjie Biotechnology Co., Ltd. for a total price of 655,100,000.00, enhancing its market position[39]. - The company has engaged with 17 counterparties to sign conditional equity transfer agreements, indicating ongoing strategic expansion efforts[26]. Revenue and Costs - Total operating revenue for Q1 2023 was approximately RMB 3.89 billion, an increase of 14.7% compared to RMB 3.39 billion in Q1 2022[30]. - Total operating costs for Q1 2023 were approximately RMB 3.87 billion, up from RMB 3.50 billion in Q1 2022, reflecting a year-over-year increase of 10.6%[30]. - The company reported a total revenue from sales of goods and services amounting to 3,574,616,196.13, compared to 3,148,399,562.50 in the previous period, reflecting growth[33].

Financial Performance - The company reported a non-operating loss of approximately ¥12.39 million in 2022, compared to a loss of ¥30.67 million in 2021, indicating a significant improvement [2]. - Government subsidies recognized in the current period amounted to ¥64.24 million, up from ¥35.44 million in 2021, reflecting a 81.3% increase [2]. - The company achieved a gain of ¥54.50 thousand from investments in subsidiaries, which is a notable recovery from a loss of ¥611.76 thousand in 2020 [2]. - The fair value changes from trading financial assets resulted in a profit of ¥3.75 million, down from ¥6.41 million in 2021, showing a decrease of 41.5% [2]. - In 2022, the company achieved operating revenue of 16.732 billion RMB, an increase of 6.5% compared to the previous year, and net profit attributable to shareholders of 302 million RMB, marking a turnaround from losses [163]. Employee and Governance - The total number of employees at the end of the reporting period was 5,067, with 56 in the parent company and 5,011 in major subsidiaries [26]. - The company has implemented an "excess profit sharing system" as part of its compensation policy to align with its strategic goals [28]. - There are no stock incentive plans for directors and senior management during the reporting period [32]. - The company has 147 employees participating in the employee stock ownership plan, holding a total of 6,363,400 shares, which is 0.47% of the total share capital [33]. - The company’s board of directors actively participated in meetings, with all members attending 12 meetings during the reporting period [50]. Internal Control and Compliance - The internal audit department has strengthened its oversight of the internal control system, enhancing compliance and risk management practices [39]. - The company has established a comprehensive internal control system in accordance with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange [39]. - The company reported zero significant deficiencies in financial reporting controls during the reporting period [41]. - There were no material weaknesses identified in internal controls, indicating a strong control environment [42]. - The company has established a robust internal control system to ensure the accuracy and completeness of financial information [91]. Environmental Responsibility - The company has complied with environmental regulations and standards, ensuring responsible operational practices [72]. - The company established an emergency response center led by the general manager to handle environmental pollution incidents, ensuring clear responsibilities and training for staff [75]. - The company has implemented automatic online monitoring equipment for wastewater treatment, measuring parameters such as chemical oxygen demand and ammonia nitrogen [79]. - The company reported a total discharge of 0.00735 tons of chemical oxygen demand and 0.000334 tons of ammonia nitrogen, with no exceedance of discharge standards [99]. - The company has a valid pollution discharge permit until October 28, 2026, for its plant protein production operations [98]. Strategic Development and Market Position - The company plans to enhance its market expansion strategies and product offerings in the upcoming fiscal year [1]. - The company is actively involved in market expansion and product development, particularly in the field of plant-based proteins [90]. - The company aims to become a leading health farming service provider and safe food supplier in China, achieving a complete closed loop in modern animal husbandry across four key areas: breeding, feed management, animal medicine, and meat processing sales [128]. - The company has completed a mixed-ownership reform in its animal health business, introducing new strategic investors and implementing employee stock ownership to enhance business focus and vitality [167]. - The company is enhancing its digital transformation efforts, focusing on cost reduction in breeding, disease prevention, and smart farming [168]. Financial Management and Future Plans - The company plans to distribute cash dividends of 2.2 RMB per 10 shares, totaling approximately 298,010,804.3 RMB (including tax) for the fiscal year 2022 [31]. - The company has committed to a cash dividend distribution of no less than 10% of the distributable profit achieved in the year, with plans for annual distributions over the next three years [118]. - The company plans to increase cash dividend ratios if net profits continue to grow steadily over the next three years [118]. - The company has committed to terminating non-core financial business operations within six months to maintain focus on its primary business [116]. - The company has made adjustments to its accounting practices regarding research and development expenditures and sales rebates, impacting its profit and tax liabilities [123][139]. Industry Insights - In 2022, China's pig inventory reached 452.56 million heads, an increase of 3.34 million heads or 0.74% year-on-year, while the slaughter volume was 699.95 million heads, up 28.67 million heads or 4.27% year-on-year [143]. - The animal vaccine industry is supported by national policies aimed at improving animal disease prevention systems, with a focus on innovation and large-scale production [146]. - The implementation of the new veterinary drug GMP standards is expected to lead to industry consolidation, improving product quality and increasing market concentration [147]. - The veterinary drug industry experienced a significant reduction in profitability in the first half of 2022, but began to recover in the second quarter, with a positive trend in revenue and profit in the third quarter [148]. - The total output of the national feed industry reached 30.223 million tons in 2022, a growth of 3.0% year-on-year, with a significant increase in bulk feed sales by 18.5% [157].

天康生物 为充分尊重投资者、提升交流的针对性，现就公司 2022 年年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。 投资者可通过访问 http://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。问题征集截至 2023 年 5 月 15 日（星期一）17:00。 公司将在 2022 年年度业绩说明会上，在信息披露允许的范围内对投资 者普遍关注的问题进行回答。 天康生物 | 证券代码：002100 | 证券简称：天康生物 | 公告编号：2023-049 | | --- | --- | --- | | 债券代码：128030 | 债券简称：天康转债 | | 天康生物股份有限公司 关于举行 2022 年年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 天康生物股份有限公司（以下简称"公司"）将于 2023 年 5 月 16 日（星期二）下午 15：00—17：00 举行 2022 年年度报告网上业绩 说明会，本次年度报告说明会将采用网络远程方式召开，投资者可登 陆 "全景·路演天下"（http:/ ...

Group 1: Business Operations - The company employs a "sales-driven production and sales" strategy to effectively control operational risks while leveraging the plant protein business to support the feed business [2] - The feed business in Xinjiang maintains good growth, while the Central Plains region experiences slow growth, and the Northeast region faces significant challenges [3] Group 2: Vaccine Business - The animal vaccine business saw substantial growth in 2014, primarily due to a surge in sales of small ruminant disease vaccines and stable growth in government tendered vaccines [3] - The company is actively seeking breakthroughs in market-oriented marketing for its vaccine products [3] Group 3: Asset Restructuring - The company has submitted feedback to the China Securities Regulatory Commission (CSRC) regarding its major asset restructuring, which is currently under review by the CSRC [3]